Novo Nordisk's CEO is not worried about blockbuster semaglutide drugs being added to Medicare drug pricing negotiations this ...
Sharon was on hand to promote the event alongside the band's originals guitarist Tony Iommi, after admitting she is ...
AbbVie’s Skyrizi was responsible for the highest TV advertising outlay in pharma in most months of 2024, but 2025 is starting ...
The Danish maker of Ozempic and Wegovy reported a 25 percent increase in sales to $40.6 billion, but said it expected slower growth this year.
In emotional scenes, the former OnlyFans model, 27, couldn't keep it together as she candidly told her co-stars that her 2022 ...
WEDNESDAY, Feb. 5, 2025 (HealthDay News) -- Hopes that GLP-1 drugs such as Ozempic and Wegovy could help slow Parkinson's ...
Novo Nordisk has a dominant position in diabetes and weight-loss drugs, strong financial growth outlook, and great potential. Click to read why NVO is a Strong Buy.
Novo Nordisk today announced 2024 earnings, reporting a 26% increase in annual sales to ~$40.56bn. Read why I upgrade NVO ...
6hon MSN
Sales of Novo Nordisk’s (NVO) blockbuster weight-loss drug Wegovy doubled in the fourth quarter, but the Danish ...
7hon MSN
Semaglutide, the drug used in Ozempic, has been linked to lowering the risk of Alzheimer's disease in the past. So, it was ...
The use of blockbuster weight loss drugs has surged among young women, for whom the treatments can often be "liberating." ...
Novo Nordisk's U.S.-listed shares are rising 4% in premarket trading after the Ozempic and Wegovy maker's better-than-estimated quarterly results offset slower 2025 sales growth projections amid ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results